Posted by Michael Wonder on 11 Feb 2025
Immix Biopharma receives FDA regenerative medicine advanced therapy designation for NXC-201, sterically optimised CAR-T for relapsed/refractory AL amyloidosis
10 February 2025 - FDA RMAT designation follows positive proof of concept US clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL amyloidosis.
Immix Biopharma today announced that the US FDA has granted RMAT designation to sterically optimised CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis.
